Medicare Drug Pricing Negotiations: Assessing Constitutional Structural Limits
A series of structural constitutional arguments lodged in multiple cases against Centers for Medicare and Medicaid Services' (CMS) authorities to negotiate prescription drug prices via the 2022 Inflation Reduction Act threaten the legitimacy of CMS program and federal agency powers.
Saved in:
Published in | The Journal of law, medicine & ethics Vol. 51; no. 4; pp. 956 - 960 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
Cambridge University Press
01.01.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | A series of structural constitutional arguments lodged in multiple cases against Centers for Medicare and Medicaid Services' (CMS) authorities to negotiate prescription drug prices via the 2022 Inflation Reduction Act threaten the legitimacy of CMS program and federal agency powers. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 About This Column James G. Hodge, Jr., J.D., LL.M., serves as the section editor for Public Health and the Law. He is the Peter Kiewit Foundation Professor of Law and Director, Center for Public Health Law and Policy, Sandra Day O’Connor College of Law, Arizona State University (ASU). |
ISSN: | 1073-1105 1748-720X |
DOI: | 10.1017/jme.2024.12 |